Multi-Modal Spatial Omics Platforms Market Key Players Analysis 2025 to 2034

Global Multi-Modal Spatial Omics Platforms Market Size is valued at USD 174.23 Mn in 2024 and is predicted to reach USD 504.55Mn by the year 2034 at a 11.4% CAGR during the forecast period for 2025 to 2034.

Multi-Modal Spatial Omics Platforms Market, Share & Trends Analysis Report, By Multi-Omic Combination (RNA + Protein, Protein + Metabolite/Lipid, RNA + DNA / Genomic features, Tri-modal (RNA + Protein + Morphology/Metabolite)), By Detection Modality (In situ imaging (cyclic IF, fluorescence), In situ hybridization / in situ sequencing, ROI-based digital spatial profiling, Imaging mass cytometry/ion beam imaging, Barcoding-based spatial transcriptomics), By Workflow Component, By Sample Type, By Spatial Resolution, By Multiplexing Capacity, By Application, By End-User, By Region, and Segment Forecasts, 2025 to 2034 

Multi-modal spatial omics platforms integrate multiple molecular layers—such as RNA, protein, and metabolites—within the same tissue section while preserving spatial context. By combining techniques like spatial transcriptomics, multiplex immunofluorescence, and imaging mass spectrometry, these platforms reveal how different biomolecules interact within intact cellular environments. This holistic approach enables researchers to study cell-to-cell communication, tissue organization, and disease mechanisms in unprecedented detail, bridging molecular biology, imaging, and data analytics into a single, unified workflow.

Multi-modal spatial omics platforms allow researchers to analyze genes, proteins, and other molecules within their native tissue context, transforming tissue analysis from bulk sampling to in situ cellular mapping. The market is entering a phase of rapid expansion as spatial proteomics, high-plex imaging, and whole-transcriptome mapping emerge as key growth areas. Driven by rising R&D in immuno-oncology, neuroscience, and precision pathology, these platforms are becoming central to biomarker discovery, drug target validation, and the evolution of quantitative, spatially informed diagnostics.

Competitive Landscape

Some of the Major Key Players in the Multi-Modal Spatial Omics Platforms Market are

• 10x Genomics
• Bruker (NanoString assets)
• Vizgen
• Miltenyi Biotec
• Standard BioTools (Fluidigm)
• Ionpath
• Lunaphore (now part of Bio-Techne)
• Bio-Techne / ACD
• Curio Bioscience
• Akoya Biosciences
• Molecular Instruments (HCR)
• Ultivue
• Other prominent players

Market Segmentation

The multi-modal spatial omics platforms market is segmented into multi-omic combination, detection modality, workflow component, sample type, spatial resolution, multiplexing level, application, and end-user. Based on the multi-omic combination, the market is segmented into RNA + protein, protein + metabolite/lipid, RNA + DNA / genomic features, and tri-modal (RNA + protein + morphology/metabolite). Based on the detection modality, the market is divided into in situ imaging (cyclic if, fluorescence), in situ hybridization / in situ sequencing, ROI-based digital spatial profiling, imaging mass cytometry/ion beam imaging, and barcoding-based spatial transcriptomics.

Based on the workflow component, the market is divided into instruments/platforms, reagents & panels, software/analytics, and services/CROs. Based on the sample type, the market is divided into subcellular, single-cell, and spot-level / ROI. Based on the multiplexing capacity, the market is divided into Low-plex (< 100 targets), Mid-plex (100 – 1,000 targets), High-plex (> 1,000 targets or whole-transcriptome. Based on the application, the market is divided into immuno-oncology / tumor microenvironment, biomarker discovery, neuroscience, inflammation & autoimmune, infectious diseases, and fibrosis. Based on the End-User, the market is divided into pharma & biotech, academic & research institutes, cros & service providers, hospitals & pathology labs.

The RNA + Protein Segment is Expected to Have the Highest Growth Rate During the Forecast Period.

The integration of RNA and protein analysis within multi-modal spatial omics platforms is a key growth driver, offering a holistic view of cellular function, tissue organization, and disease mechanisms at unparalleled resolution. Spatial transcriptomics maps gene expression within its native tissue context, revealing how genes behave in specific cell types or locations. Combining RNA and protein profiling enables the discovery of novel biomarkers and therapeutic targets, supporting precision medicine and advancing targeted drug development, particularly in complex areas such as tumor microenvironment research.

The FFPE Segment Dominates the Market

FFPE samples remain the cornerstone of clinical diagnostics and biobanking due to their global availability and stability. Their widespread use allows researchers to conduct retrospective spatial omics studies without the need for new tissue collection, reducing costs and logistical hurdles. FFPE’s dominance in pathology and oncology stems from its compatibility with RNA and protein mapping, enabling biomarker discovery and tumor microenvironment analysis. Ongoing improvements in RNA retrieval and antibody-based detection continue to enhance its value in multi-modal spatial omics.

North America Has the Largest Market Share During the Forecast Period.

North America is home to prestigious colleges and renowned research organisations like the National Institutes of Health, which create an atmosphere that is favourable for advances in spatial omics. By consistently creating and improving cutting-edge spatial omics platforms, well-known American businesses like 10x Genomics and NanoString Technologies have made a substantial contribution to the market. Research and the commercialization of these technologies have been further pushed by government financing programs and initiatives, such as those from the National Cancer Institute. North America is now a centre for precision medicine and advanced diagnostics due to the combination of strong regulatory frameworks and advantageous trade policies, which have also boosted market expansion.

Recent Developments:

·       In October 2025, SPT Labtech, a pioneer in the design and development of laboratory automation and liquid handling solutions, and 10x Genomics, Inc. announced a strategic partnership to provide automated workflows for single cell research. The collaboration will allow scientists to scale experiments on 10x’s Chromium Single Cell platform, with planned future expansion to the Visium Spatial platform, by providing plug-and-play protocols on SPT Labtech’s firefly® liquid handling platform.

·       In October 2025, Bruker announced FDA clearance of claims 7 and 8 for the MALDI Biotyper® CA System, expanding diagnostic capabilities. The MALDI Biotyper CA System is a mass spectrometry-based platform that uses MALDI-TOF technology for rapid identification of microorganisms following culture from human specimens, either from isolated colonies or positively flagged blood cultures.

Multi-Modal Spatial Omics Platforms Market Report Scope